FIBRINOPEPTIDE A

GenWay ID: GWB-103FDF
Legacy ID: 10-783-79540
Size: 0.2 mg
Reactivity: Human
purchase this item
$150.00

* Required Fields

Details for FIBRINOPEPTIDE A

Specificity: FIBRINOPEPTIDE A Preparation: Solid phase synthesis

Preservative Stabilisers: None present

Reconstitution: Reconstitute with sterile distilled water. For long term storage, addition of a preservative is recommended. Function: Fibrinogen has a double function: yielding monomers that polymerize into fibrin and acting as a cofactor in platelet aggregation.

Subunit: Heterohexamer; disulfide linked. Contains 2 sets of 3 non-identical chains (alpha, beta and gamma). The 2 heterotrimers are in head to head conformation with the N-termini in a small central domain.

Subcellular Location: Secreted.

Domain: A long coiled coil structure formed by 3 polypeptide chains connects the central nodule to the C-terminal domains (distal nodules). The long C-terminal ends of the alpha chains fold back, contributing a fourth strand to the coiled coil structure.

Ptm: The alpha chain is not glycosylated.

Ptm: Forms F13A-mediated cross-links between a glutamine and the epsilon-amino group of a lysine residue, forming fibronectin-fibrinogen heteropolymers.

Ptm: About one-third of the alpha chains in the molecules in blood were found to be phosphorylated.

Ptm: Conversion of fibrinogen to fibrin is triggered by thrombin, which cleaves fibrinopeptides A and B from alpha and beta chains, and thus exposes the N-terminal polymerization sites responsible for the formation of the soft clot. The soft clot is converted into the hard clot by factor XIIIA which catalyzes the epsilon-(gamma-glutamyl)lysine cross-linking between gamma chains (stronger) and between alpha chains (weaker) of different monomers.

Disease: Defects in FGA are a cause of congenital afibrinogenemia [MIM:202400]. This is a rare autosomal recessive disorder characterized by bleeding that varies from mild to severe and by complete absence or extremely low levels of plasma and platelet fibrinogen. The majority of cases of afibrinogenemia are due to truncating mutations.

Disease: Variations in position Arg-35 (the site of cleavage of fibrinopeptide a by thrombin) leads to alpha-dysfibrinogenemias.

Disease: Defects in FGA are a cause of amyloidois type 8 (AMYL8) [MIM:105200]; also known as systemic non-neuropathic amyloidosis or Ostertag-type amyloidosis. AMYL8 is a hereditary generalized amyloidosis due to deposition of apolipoprotein A1, fibrinogen and lysozyme amyloids. Viscera are particularly affected. There is no involvement of the nervous system. Clinical features include renal amyloidosis resulting in nephrotic syndrome, arterial hypertension, hepatosplenomegaly, cholestasis, petechial skin rash.

Similarity: Contains 1 fibrinogen C-terminal domain.

Additional Info for FIBRINOPEPTIDE A

Related Product Names SYNTHETIC HUMAN FIBRINOPEPTIDE A FIBRINOPEPTIDE AFGA
NCBI Acc Number NP_000499.1
Purity HPLC: >97%
Format Purified
Stability 18 months from date of despatch.
Storage Prior to reconstitution store at +4 degree C.
After reconstitution store at -20 degree C.
Storage in frost-free freezers is not recommended. This product should be stored undiluted.
Avoid repeated freezing and thawing as this may denature the ant
Molecular Weight 94973
Applications ELISA

GenWay Trust

Of course we value your privacy and your data security but most of all we value your trust.
Online Payments
GenWay Biotech Inc is a BBB Accredited Business. Click for the BBB Business Review of this Laboratories - Research & Development in San Diego CA